Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN496 Open-Label Extension in Pediatric KCNQ2-DEE
NCT04912856Phase 3Terminated
- Sponsor
- Xenon Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, double-blind trial of retigabine in KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE), sponsored by Xenon Pharmaceuticals. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events Related to Intervention. Started Aug 2021; status: terminated.
02
Drugs
retigabine
03
Conditions
KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)
Beyond the preview
Go deeper on NCT04912856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912856.